ALK and neuroblastoma: In this report, we have validated immunoassays to detect ALK and phosphorylated ALK in vitro, successfully applied them to an in vivo model of neuroblastoma, and demonstrated a quantitative difference in on‐target pharmacodynamic changes between a first‐ and second‐generation ALK inhibitor.